Evidence map›Paper›PMID 40437624›Full record

SynthesisAntimicrobial resistance and infection control2025

The neglected model validation of antimicrobial resistance transmission models - a systematic review.

Maja L Brinch, Andrea Palladino, Jeroen Geurtsen, Thierry Van Effelterre, Lorenzo Argante, Michael J McConnell, Lene Christiansen, Michelle A Pihl, Natasja K Lund, Tine Hald

Abstract readSystematic Review
In one paragraph

Synthesis in Antimicrobial resistance and infection control, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Maja L BrinchRisk-Benefit, DTU National Food Institute, Kgs. Lyngby, Denmark. malbri@food.dtu.dk.
Andrea PalladinoGSK, Siena, Italy.
Jeroen GeurtsenBacterial Vaccines Discovery & Early Development, Janssen Vaccines & Prevention B.V, Leiden, The Netherlands.
Thierry Van EffelterreJohnson & Johnson, Global Commercial Strategy Organization, Beerse, Belgium.
Lorenzo ArganteGSK, Siena, Italy.
Michael J McConnellDepartment of Biological Sciences, University of Notre Dame, Notre Dame, USA.
Lene ChristiansenRisk-Benefit, DTU National Food Institute, Kgs. Lyngby, Denmark.
Michelle A PihlRisk-Benefit, DTU National Food Institute, Kgs. Lyngby, Denmark.
Natasja K LundRisk-Benefit, DTU National Food Institute, Kgs. Lyngby, Denmark.
Tine HaldRisk-Benefit, DTU National Food Institute, Kgs. Lyngby, Denmark.

Funding

Innovative Medicines Initiative No 101034420
6 · The paper itself

Abstract

backgroundIn the fight against antimicrobial resistance, mathematical transmission models have been shown as a valuable tool to guide intervention strategies in public health.

objectiveThis review investigates the persistence of modelling gaps identified in earlier studies. It expands the scope to include a broader range of control measures, such as monoclonal antibodies, and examines the impact of secondary infections.

methodsThis review was conducted according to the PRISMA guidelines. Gaps in model focus areas, dynamics, and reporting were identified and described. The TRACE paradigm was applied to selected models to discuss model development and documentation to guide future modelling efforts.

resultsWe identified 170 transmission studies from 2010 to May 2022; Mycobacterium tuberculosis (n = 39) and Staphylococcus aureus (n = 27) resistance transmission were most commonly modelled, focusing on multi-drug and methicillin resistance, respectively. Forty-one studies examined multiple interventions, predominantly drug therapy and vaccination, showing an increasing trend. Most studies were population-based compartmental models (n = 112). The TRACE framework was applied to 39 studies, showing a general lack of description of test and verification of modelling software and comparison of model outputs with external data.

conclusionDespite efforts to model antimicrobial resistance and prevention strategies, significant gaps in scope, geographical coverage, drug-pathogen combinations, and viral-bacterial dynamics persist, along with inadequate documentation, hindering model updates and consistent outcomes for policymakers. This review highlights the need for robust modelling practices to enable model refinement as new data becomes available. Particularly, new data for validating modelling outcomes should be a focal point in future modelling research.

Indexed as

Drug Resistance, BacterialModels, TheoreticalAnti-Bacterial AgentsHumansMycobacterium tuberculosisStaphylococcal InfectionsStaphylococcus aureusValidation Studies as TopicAnti-Bacterial AgentsAntimicrobial resistanceInterventionsSystematic reviewTrace criterionTransmission modelling

Identifiers

PMID40437624
PMCPMC12121249

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.